Herbert Smith Freehills Kewei advises Sanofi on US$15 million cornerstone investment in ClouDr 科伟史密夫斐尔联营办公室为赛诺菲完成1500万美元基石投资提供法律服务

Leading international law firm Herbert Smith Freehills and its joint operation partner Kewei have advised global healthcare company Sanofi on its participation in the initial public offering and listing of ClouDr in Hong Kong as a cornerstone investor, a Chinese technology solutions services provider for healthcare companies listed on the Stock Exchange of Hong Kong on 6 July. This transaction is the first time Sanofi participates in a Hong Kong IPO as a cornerstone investor.

Sanofi is one of the largest pharmaceutical companies in Europe, listed on EURONEXT (SAN) and NASDAQ (SNY). Sanofi made an investment of US$15 million into ClouDr as a cornerstone investor in its global offering.

"We are delighted to have advised Sanofi on this landmark transaction," said Kewei international partner Gavin Guo. "Healthcare is a priority sector for both Herbert Smith Freehills and Kewei, and we are advising a growing number of clients in this sector on both corporate matters and disputes."

"Congratulations to Sanofi on this successful cornerstone investment in Hong Kong, where is now a leading hub for healthcare investors," said Hong Kong partner Jeremy Shen, "We are delighted to have assisted in this high-profile investment, which reflects the continued depth and breadth of the investor pool in the Hong Kong market." 

Gavin led a Kewei team advising on PRC legal issues relevant to the investment target, supported by senior consultant Angela Zhao and associate Alvin Zheng. Jeremy led a Hong Kong team advising the client, from regulatory requirements relevant to its investment as cornerstone investor in a Hong Kong IPO to negotiating the cornerstone investment agreement. Senior associate Jaime Fong and associate Bryan Cheung provided support.

全球领先的律师事务所史密夫斐尔与科伟律师事务所的联营办公室为全球医疗健康公司赛诺菲作为基石投资者参与智云健康在香港首次公开募股和上市提供咨询。智云健康是一家为医疗健康公司提供技术解决方案的中国企业，于7月6日在香港联交所上市。这笔交易是赛诺菲首次以基石投资者身份参与香港IPO。

赛诺菲是欧洲最大的制药公司之一，在泛欧交易所（SAN）和纳斯达克（SNY）上市。赛诺菲作为智云健康全球发行的基石投资者投资1500万美元。

科伟律师事务所国际资深顾问郭武汉律师（Gavin Guo）表示：“我们非常荣幸为赛诺菲就这笔里程碑式的交易提供咨询。对于史密夫斐尔和科伟来说，医疗健康都是我们的核心业务之一。我们正在为越来越多的医疗健康行业客户就公司事务和争议解决事务提供法律服务。”

史密夫斐尔香港办公室合伙人沈志良律师（Jeremy Shen）表示：“祝贺赛诺菲在香港成功完成这笔基石投资，目前香港已成为医疗健康行业投资者汇聚的中心。我们很高兴为这项备受瞩目的交易提供协助，这反映了香港市场投资者的深度和广度。” 

郭武汉律师率领科伟团队就与投资目标相关的中国法律提供建议，资深顾问赵秋丹和郑天骅（Associate）提供支持。沈志良律师率领香港办公室团队为客户提供咨询，包括为其作为香港IPO基石投资者的投资相关监管要求提供建议以及进行基石投资协议谈判。方靖颐（Senior Associate）和张皓阳（Associate）提供支持。